HSDT trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes HSDT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Solana Company (HSDT) has a Wall Street consensus price target of N/A, based on estimates from 5 covering analysts. The company has a market capitalization of $113M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, HSDT trades at a trailing P/E of -1.0x. Analysts expect EPS to grow +18.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 STIMNeuronetics, Inc. | $150M | $2.15 | $5.00 | +132.6% | Buy | — | 8 |
 LFSTLifeStance Health Group, Inc. | $5.3B | $13.77 | $14.14 | +2.7% | Buy | 84.9x | 11 |
 MBOTMicrobot Medical Inc. | $51M | $1.11 | $5.50 | +395.5% | Buy | — | 3 |
 GKOSGlaukos Corporation | $13.2B | $224.41 | $218.70 | -2.5% | Buy | 332.7x | 25 |
 NVCRNovocure Ltd | $1.5B | $13.28 | $26.00 | +95.8% | Buy | — | 15 |
 LIVNLivaNova PLC | $4.9B | $89.99 | $100.00 | +11.1% | Buy | 20.7x | 15 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
Quick answers to the most common questions about buying HSDT stock.
The consensus price target for HSDT is $N/A, close to the current price of $1.93 (N/A% implied move). Based on 5 analyst estimates, the stock appears fairly valued near current levels.
HSDT has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
HSDT's current price is $1.93 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for HSDT, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
HSDT is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month HSDT stock forecast based on 5 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
HSDT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
HSDT analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.